CalciMedica's Participation in H.C. Wainwright's Kidney Conference
CalciMedica Inc., a biopharmaceutical company at the forefront of developing innovative therapies, announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. Taking place on July 14, 2025, this event will feature a fireside chat with Dr. Rachel Leheny, the company's CEO. The discussion will highlight the latest advancements in calcium release-activated calcium (CRAC) channel inhibition therapies, crucial for treating a range of acute and chronic inflammatory and immunologic diseases.
Understanding CalciMedica
CalciMedica is not just another biopharmaceutical organization; it's a pioneer in tackling life-threatening conditions for which there are no current approved therapies. Their primary focus is on developing CRAC channel inhibition therapies that can significantly modulate immune responses while protecting against tissue cell damage. This innovative approach aims to bring therapeutic solutions to patients suffering from severe illnesses.
Their flagship product candidate, Auxora™, has successfully demonstrated positive outcomes across numerous clinical trials, offering hope to critically ill patients affected by conditions like acute pancreatitis and COVID pneumonia. With over 350 patients receiving treatment, Auxora™ has shown a promising safety profile, supporting its efficacy in managing these challenging health issues.
Upcoming Conference Highlights
During the H.C. Wainwright conference, key discussions will revolve around CalciMedica's competitive edge in the biopharmaceutical landscape and the role of CRAC channel inhibition in advancing treatment options for kidney injury and other inflammatory conditions. Attendees can expect the presentation to shed light on various ongoing clinical trials, including:
- - Phase 2b (CARPO) focused on patients suffering from acute pancreatitis accompanied by systemic inflammatory response syndrome.
- - Phase 2 (CARDEA) targeting individuals with COVID-related pneumonia.
- - Phase 2 (KOURAGE) that investigates acute kidney injury with associated hypoxemic respiratory failure.
The live webcast of Dr. Leheny's session will be available in the